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Abstract  
In a human intervention study comprising 49 healthy participants, coffee combining 
natural green coffee bean constituents and dark roast products was identified as a 
genotype-dependent inducer of Nrf2, significantly affecting Nrf2 gene expression and 
downstream transcription. Specifically, with 65% of participants showing ≥1.5 fold 
increase in Nrf2-transcription, the presence of the -651G/A SNP in the Nrf2 gene in 
conjunction with heterozygosity of the 6/7 AT repeat sequence in the UGT1A1 gene 
significantly down-regulated coffee-mediated gene expression. Considering the role 
of the Nrf/ARE pathway in the regulation of antioxidative and chemopreventive phase 
II efficacy, individual genotype must be considered when examining the potency of 
bioactive food/food constituents and therapeutic potential. 
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Introduction 
Phase II enzymes play a critical role in converting reactive electrophiles or 
xenobiotics into less toxic products and seem to be crucial for cancer prevention, with 
deficiency in phase II enzymatic activity associated with increased risk of colon 
cancer [1, 2]. The expression of many phase II genes is regulated via the activation 
of antioxidant response elements (ARE), located in the 5’-flanking region of their 
respective promoters. Activation by ROS or upstream protein kinases induces 
translocation of the transcription factor Nrf2 (Nuclear factor-erythroid 2 p45 subunit 
(NF-E2)-related factor 2) from the cytoplasm into the nucleus, binding to ARE and 
subsequent transcription of phase II enzymes, including glutathione S-transferases 
(GST), UDP-glucuronyl transferases (UGT) or γ-glutamyl cysteine ligase (γGCL) [3-
12]. During a human intervention trial, we recently, identified the typical dark roast 
coffee constituent N-methylpyridinium (NMP) as well as the green bean constituent n-
chlorogenic acid (CGA), as potent activators of the Nrf2/ARE pathway [13]. Over four 
weeks, participants consumed the study coffee, a blend combining both these 
constituents (typical dark roast characteristics as NMP with considerable amounts of 
green bean constituents) resulting in a significant increase in mean Nrf2 gene 
transcripts in peripheral blood lymphocytes (PBLs) [14, 15]. However, large 
differences in Nrf2 activation ability were identified in participants, which could not be 
explained by differences in their general health status or nutritional behavior.  
Previous reports have highlighted genetic variation in specific antioxidative genes 
determine their ability to be activated by bioactive food compounds [16]. In addition, 
biochemical studies have associated allelic variations in the Nrf2 promoter region 
with differences in antioxidative phase II gene transcription [17]. To date, 9 single 
nucleotide polymorphisms (SNPs) have been identified in the Nrf2 gene [17-19]. Of 
relevance are the -617C/A and the -651G/A SNPs, located within the promoter 
region. Both SNPs have been shown to reduce Nrf2 transcriptional activity reflected 
by attenuated binding of Nrf2 to the ARE, resulting in decreased Nrf2 transcription 
[17]. Genotyping of a subset of individuals from our previous study indicated a 
connection between Nrf2 genotype and response to coffee [15]. Based on these 
findings, we undertook the current intervention trial to (a) test Nrf2-activation potential 
of the study coffee in a larger cohort; and (b) to determine whether individual 
differences in response to the study coffee is associated with specific genotypes of 
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the Nrf2, GST1A1 and UGT1A1 genes. 
 
Results  
Nrf2 genotype and gene transcription 
A 424bp polymorphic region of the Nrf2 promotor was sequenced in all 49 
participants of the intervention trial to examine the -617C/A, the -653A/G and the -
651G/A polymorphisms, already determined to be functionally relevant for 
transcriptional activity of the Nrf2 gene [17]. The -617C/A SNP was present in 10/49 
(20%) of participants (Table 1). The presence of the -651G/A SNP was observed in 
15/49 individuals (31%) while 31/49 (63%) of the participants possessed a SNP at 
position -653A/G.  
 
Table 1 
Genotype distribution of Nrf2, GST1A1 and UGT1A1 in participants of the coffee 
intervention study 
Gene SNP  Frequency  Literature  Ref. 
   n [%] N [%]  
Nrf2 -617C/C (WT) 39/49 80 16/20 80 [17] 
 -617C/A 10/49 20 4/20 20 [17] 
 -651G/G (WT) 34/49 69 18/20 90 [17] 
 -651G/A 15/49 31 2/20 10 [17] 
 -653A/A (WT) 18/49 37 15/20 75 [17] 
 -653A/G 31/49 63 5/20 25 [17] 
GST1A1 A/A (WT) 24/48 50 106/27 38 [20] 
 A/B 18/48 38 133/27 48 [20] 
 B/B 6/48 12 39/278 14 [20] 
UGT1A1 [TA]6TAA (WT) 21/46 46 183/399 46 [23] 
 [TA]6/7TAA 19/46 41 169/399 42 [23] 
 [TA]7TAA 6/46 13 47/399 12 [23] 
 
 
Changes in Nrf2 gene transcription were also assessed at the different blood 
collection points (CPs) in the course of the study. A potent induction of Nrf2 gene 
transcription after four weeks consumption of the study coffee (BC3) in comparison to 
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both wash-out (BC2) as well as normal diet (BC1) was demonstrated (Figure1A). In 
total, 65% (32/49) of all participants displayed a ≥1.5-fold induction of Nrf2 gene 
transcription following coffee consumption. When we more closely examined the 
genotype-dependent magnitude of the Nrf2 activation, it was clear that the -651 SNP 
carriers displayed a weaker Nrf2 activation after coffee consumption (BC3) when 
compared to WT and the other genotype combinations (Figure 1B). Comparing the 
sensitivity of the response between all genotypes demonstrated that individuals 
carrying both the -617 and the -651 SNP concomitantly possessed the lowest 
potential to activate Nrf2 gene transcription (see supporting information, Figure S1). 
 
Figure 1A 
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Figure 1B 
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Legend Figure 1 
(A) Modulation of Nrf2 gene transcription in PBLs of 49 participants of the 
intervention trial (samples of two participants failed to show sufficient fluorescence 
signals/amplification). The data, analyzed in triplicate are presented as BOX-
diagrams, normalized to ß-actin expression and as relative transcription of individual 
levels of each participant before the study (BC1), after a four week wash-out 
(polyphenol-poor diet and no coffee consumption, BC2), after four weeks of daily 750 
mL coffee consumption (BC3), after a second wash-out period of four weeks (BC4). 
The data are represented as relative transcription of BC2=1. BC: blood collection. (B) 
Nr2 genotype dependent magnitude of changes in Nrf2 gene transcription during the 
course of the trial. The data are the mean ± SD of the individuals, grouped according 
to their respective genotypes and presented as relative transcription of BC2 (wash-
out) =1. Significances indicated are calculated by Student’s t test (#p<0.05 and ***, 
###p<0.001). BC: blood collection. 
 
GST1A1 genotype and gene transcription 
We next examined the GST1A1 polymorphism comprised of the two alleles, 
GST1A1*A and GST1A1*B [20]. The two genotypes differ in three linked base 
changes in the 5’-regulatory region of the gene (a T/G change at -567, a C/T change 
at -69 and G/A change at -52). Presence of the C/T base change at position -69 
(GST1A1*B) gives rise to an Ear1 restriction site, resulting in two fragments of 380bp 
and 100bp following digestion. GST1A1*A homozygotes show only one band at 
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480bp (see supporting information, Figure S2). From the intervention trial, 24/48 
(50%) of participants were found to carry the A/A genotype, 18/48 (38%) the 
heterozygous A/B genotype and 6/48 (12%) the rare homozygous B/B genotype 
(Table 1). We then investigated whether four weeks of intervention with the study 
coffee modulated GST1A1 transcription levels, an important member of the 
antioxidative GST enzyme family. GST1A1 gene transcription was potently elevated 
in the majority of participants after four weeks consumption of coffee (BC3) in 
comparison to the wash-out phase (BC2, Figure 2A). Stratification of participants with 
respect to coffee response demonstrated that 54% of study participants displayed a 
≥1.5-fold induction of GST1A1 transcription following coffee consumption. 
Furthermore, this group termed “coffee responders”, also displayed a higher 
induction of Nrf2 transcription during the BC1 phase of the study where participants 
followed their normal diet (Figure 2A). When we compared GST1A1 genotype in 
relation to changes in GST1A1 transcription, no significant difference in GST1A1 
activation was evident. However, individuals possessing the homozygous BB 
genotype appeared to be slightly more susceptible to changes in GST1A1 gene 
expression following coffee consumption (see supporting information, Figure S3). 
The GST1A1 gene carries an ARE sequence in its promotor region, hence its 
transcription is activated by Nrf2. Our data clearly demonstrates the transcriptional 
activity of Nrf2 and subsequently the ability to activate ARE-dependent genes 
appears to be dependent on the specific Nrf2 genotype of the individual. In addition, 
there appears to be a magnitude effect of Nrf2 genotype-dependent GST1A1 
activation. Participants carrying the -651SNP (31% of the participants), showed no 
increase in GST1A1 gene transcription after coffee consumption (Figure 2B). Thus, 
individuals, possessing the -651 SNP in their Nrf2 gene were disadvantaged in the 
antioxidative potential of the study coffee in comparison to individuals lacking this 
SNP, indicating the importance of Nrf2 genotype on antioxidative GST1A1 response. 
 
Figure 2A 
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Figure 2B 
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Legend Figure 2 
(A) Modulation of the GST1A1 gene transcription in PBLs of 48 participants of the 
intervention trial (samples of three participants failed to show sufficient fluorescence 
signals/ amplification). The data, performed in triplicate are presented as BOX-
diagrams, normalized to ß-actin expression and as relative transcription of individual 
levels of each participant before the study (BC1), after a four-week wash-out 
(polyphenol-poor diet and no coffee consumption, BC2), after four weeks of daily 
750mL coffee consumption (BC3), after a second wash-out period of four weeks 
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(BC4). The data are represented as relative transcription of BC2=1. BC: blood 
collection. (B) Nrf2 genotype dependent magnitude of changes in GST1A1 gene 
transcription during the course of the human intervention trial. The data are the mean 
± SD of the individuals, grouped according to their respective genotypes and 
presented as relative transcription of BC2 (wash-out) =1. Significances indicated are 
calculated by Student’s t test (*, #p<0.05 and ***, ###p<0.001). BC: blood collection. 
 
 
UGT1A1 represents another important phase II gene in cellular detoxification 
processes. With activation of UGT1A1 gene transcription previously reported in a 
murine model [21], we next examined changes of UGT1A1 gene transcription in the 
study participants. UGT1A1 possesses a known variation in its promotor sequence 
[22], with an additional TA repeat in the TATA region (7 TA repeats; UGT1A1*28) 
known to markedly decrease UGT1A1 expression resulting in reduced activity [22, 
23]. Most participants of the present intervention trial were found to possess either a 
homozygote [TA]6/6-repeat sequence (wild type, 21/46 individuals (46%)) or were 
heterozygous ([TA]6/7 (19/46 individuals (41%)), whereas only 13% (6/46) of the 
individuals were identified as homozygous [TA]7/7-repeat sequence carriers (Table 1). 
Although a wide variation in UGT1A1 transcription levels amongst participants was 
detected at the early timepoint (BC1, Figure 3A), the affect on transcription in 
response to coffee following adherence to the trial conditions was more evident at the 
BC3 stage of the trial. On average, induction of UGT1A1 gene transcription was 
observed in participants after four weeks intervention with the study coffee. 
Furthermore, the absence of coffee during the second wash-out period (BC4) 
resulted in down-regulation of UGT1A1 gene expression to basal levels, emphasizing 
the study coffee constituents crucial for the expression induced at BC3. When we 
stratified the participants into responders (BC3 ≥1.5) and non-responders (BC3 <1.5), 
63 % of individuals were identified as coffee responders, supporting our previous 
findings on activation of UGT1A1 gene transcription by the study coffee. Although 
UGT1A1 transcription was previously defined in a murine model, this is the first time 
this has been demonstrated in humans (Figure 3A). We then correlated changes in 
UGT1A1 transcription with participant UGT1A1 genotype during the response to 
coffee intervention period (BC3). This revealed a clear and significant correlation 
between reduced response to coffee in the presence of the 6/7 heterozygous 
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genotype (Figure 3B). Individuals carrying either the homozygous 6/6 or the 
heterozygous 7/7 genotype appeared to respond equally to the study coffee. 
Correlating UGT1A1 gene transcription with Nrf2 genotypes indicated the -651 Nrf2 
genotype was associated with a lower coffee-mediated increase in gene 
transcription. In addition, these individuals showed no increase in UGT1A1 gene 
expression following coffee consumption at BC3 when compared to the wash-out at 
BC2. In contrast, WT individuals or -617 or -653 SNP variants displayed a marked 
increase of UGT1A1 gene transcription following coffee consumption (Figure 3C). 
Linking participant response to the study coffee and genotype, clearly demonstrated 
that 63% (5/8) of individuals carrying both the 6/7 UGT1A1 and the -651 Nrf2 
genotype belonged to the group of coffee non-responders, suggesting a strong 
correlation between genetic background and response to coffee. 
Figure 3A 
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Figure 3B 
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Figure 3C 
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Legend Figure 3 
(A) Modulation of the UGT1A1 gene transcription in PBLs of 46 participants of the 
human intervention trial (samples of five participants failed to show sufficient 
fluorescence signals/ amplification). The data, performed in triplicate are presented 
as BOX-diagrams, normalized to ß-actin expression and as relative transcription of 
individual levels of each participant before the study (BC1), after a four week wash-
out (polyphenol-poor diet and no coffee consumption, BC2), after four weeks of daily 
750mL coffee consumption (BC3), after a second wash-out period of four weeks 
(BC4). The data are represented as relative transcription of BC2=1. BC: blood 
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collection. (B) UGT1A1 genotype dependent magnitude of changes in UGT1A1 gene 
transcription during the course of the human intervention trial. The data are the mean 
± SD of the individuals, grouped according to their respective genotypes and 
presented as relative transcription of BC2 (wash-out) =1. (C) Nrf2 genotype 
dependent magnitude of changes in UGT1A1 gene transcription during the course of 
the human intervention trial. The data are the mean ± SD of the individuals, c 
grouped according to their respective genotypes and presented as relative 
transcription of BC2 (wash-out) =1. Significances indicated are calculated by 
Student’s t test (*, #p<0.05, **p<0.01 and ***, ###p<0.001). BC: blood collection. 
 
Discussion  
In this study, for the first time coffee was identified as a potent inducer of the 
antioxidative and chemopreventive Nrf2/ARE pathway in humans. This was clearly 
demonstrated by a significant increase in Nrf2, GST1A1 and UGT1A1 gene 
transcription after four weeks of coffee consumption in the mean of the 51 
participants. Although this trend was clear, differences in individual responses to the 
study coffee (Figure 1A, 2A, 3A) were also observed. Examining this data more 
closely, the response of each participant for each of the genes examined revealed a 
clear group of responders (Nrf2 65% (32/49); GST1A1 54% (26/48) and UGT1A1 
63% (29/46)) having a ≥1.5 fold increase in gene transcription following coffee 
intervention (BC3) when compared to the wash-out period (BC2). A smaller group of 
non-responders (Nrf2 35% (17/49); GST1A1 46% (22/48) and UGT1A1 37% (17/46)) 
with a <1.5 fold increase observed in gene transcription following coffee consumption 
was also identified. These clear differences in gene expression in response to the 
study coffee, could not be explained by differences in dietary uptake of any 
antioxidants in participant including general diet, specific foods consumed, coffee 
intake as well as gender, ethnicity or age. In order to elucidate any genotypic 
involvement, i.e. the presence of specific allele or alleles influencing response to 
coffee, we examined regions within the Nrf2, GST1A1 and UGT1A1 genes, carrying 
known polymorphisms previously demonstrated to affect transcriptional activity [15, 
17, 20, 22, 23].  
Allele frequencies for the most common Nrf2 SNPs examined were in concordance 
with current literature and available data (Table 1). The -617C/A SNP was present in 
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10/49 (20%) of participants and the -651G/A SNP was observed in 15/49 individuals 
(31%), with 31/49 (63%) of the participants displaying a SNP at position -653A/G. 
Thus, data from the study demonstrate a higher incidence of the -653 SNP in the 
Nrf2 promotor. This is in line with previously published data [15], but is higher than 
data published by Marzec et al. (2007). However, when we combine data from the 
current study (51 individuals) with the two previous studies (n=20 in Marzec et al 
(2007) and n=18 in [15] et al) incidence of the -653 SNP is 56-63% in Caucasians.  
When we next examined a polymorphism in the GST1A1 gene (alleles GST1A1*A 
and GST1A1*B [21], 24/48 (50 %) of the participants were identified as A/A carriers, 
18/48 (38%) possessed the heterozygous A/B genotype and 6/48 (12%) were 
identified as B/B carriers (Table 1). The frequency of the GST1A1 genotypes was 
comparable to other studies in Caucasians [20] indicating the study data appears to 
represent an average population profile.  
The UGT1A1 gene possesses the known variation UGT1A1*28, the incidence of 
which varies amongst ethnicities, highest in African (43%) or European (54%) 
descended individuals and lowest in those of Asian (16%) descent [23]. The study 
population displayed a ratio of genotypes within the expected range (Table 1) with 
21/46 individuals (46%) WT ([TA]6/6-repeat) and 19/46 participants (41%) 
heterozygous ([TA]6/7-repeat). Of those examined, 6/46 individuals (13%) carried a 
homozygous [TA]7/7-repeat sequence, the low frequency of this genotype is 
supported by previous data in the literature [23]. 
Analysing the changes in gene transcription of Nrf2, GST1A1 and UGT1A1 during 
the course of the two-month trial with respect to individual genotypes revealed 
several associations. In particular, a genotype-dependent response to the study 
coffee was observed for the -651 SNP of Nrf2. Individuals carrying this genotype 
showed a considerably lower magnitude of induction in Nrf2 gene transcription during 
the coffee intervention period (BC3) when compared to participants carrying the WT 
sequence (a -617 or -653 SNP) (Figure 1B).  
Transcription of the UGT1A1 gene was significantly up-regulated in 63% of 
participants in this study. The UGT1A1 gene also demonstrated the strongest 
variation in the response to the study coffee in association with genotype. Both the 
magnitude of the response, as well as the frequency of induced UGT1A1 gene 
transcription following coffee consumption was significantly decreased in carriers 
possessing a heterozygous 6/7 sequence in the promotor region. From the study, 
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18/51 (35%) individuals carried this genetic modification and most of these 
individuals failed to increase UGT1A1 gene transcription following coffee 
consumption (Figure 3B). 
Previous studies have reported reduced Nrf2 transcriptional activity affecting 
downstream ARE-dependent gene transcription in individuals carrying genetic 
variations in the Nrf2 promotor [17, 18]. In the present study, individuals carrying the 
SNP at -651 in the Nrf2 gene demonstrated a significantly reduced response to 
coffee, correlating to a significantly lower induction of Nrf2-dependent GST1A1 and 
UGT1A1 gene transcription (Figure 2B, 3C). These findings are supported by Marzec 
et al. (2007) who detected a reduced transcriptional activity of Nrf2, reflected by an 
attenuated binding of Nrf2 to the ARE (EpRE) in the presence of the -651 SNP. 
Furthermore, individuals carrying this genetic variation seem to suffer more frequently 
from acute lung injury (ALI), a disease, related to reduced antioxidative cell defence 
[17]. In addition, the genotype specific response of the UGT1A1 gene is interesting, 
as previous research in Gilbert’s Syndrome has indicated that the [TA]7/7-repeat 
genotype was associated with increased bilirubin and thus reduced enzymatic activity 
[22]. That the [TA]6/7-repeat genotype displayed reduced induction of the gene in 
response to coffee in our study may reflect some kind of interference between the 
alleles in mediating gene response, perhaps some kind of asymmetric recruitment of 
transcription factors that slows response efficiency not present in homozygous 
individuals. This may also be a reflection of the relatively low numbers of [TA]6/6-
repeat individuals in the study reducing our ability to accurately determine the 
response in this group. This kind of variable response is worthy of additional follow-
up in larger cohorts and mechanistic models, to determine its validity. The overall 
findings of this study demonstrate the influence of genotype on general/physiological 
gene transcription. We have expanded this to examine the effect of Nrf2 genotype on 
transcriptional activation after food intervention.  
Taken together, the study coffee, combining potent Nrf2 inducers from green coffee 
beans with typical high roasted constituents, has been identified as a potent inducer 
of antioxidative cell protection in the mean of participants in a two-month coffee 
intervention trial. Differences in the coffee response within the study population 
resulted in the identification of a group of responders and non-responders for 
transcription of Nrf2, GST1A1 and UGT1A1 in peripheral blood lymphocytes. In 
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addition, the frequency of the -651 SNP in the Nrf2 gene as well as the presence of a 
heterozygous 6/7 sequence in the downstream Nrf2-dependent phase II gene 
UGT1A1 potently down-regulated an individual’s ability to respond to coffee with 
increased antioxidative gene transcription.  
Here, we have demonstrated downstream effects on transcriptional regulation within 
the antioxidative phase II pathway dependent upon the genotype of the key 
transcriptional regulator Nrf2. We therefore suggest that genotype must be 
considered when determining criteria to evaluate treatment and outcome strategies in 
human antioxidant interventions and therapies. Specifically, genotype needs to be 
considered when targeting Nrf2-dependent gene response in order to estimate the 
chemopreventive potency of bioactive food/food constituents. With phase II 
enzymatic activity implicated in risk of several cancers, our ability to monitor and 
manipulate this important pathway has enormous therapeutic potential.  
Methods 
Coffee brew 
The study coffee brew consisted of a special roasted and blended Arabica coffee, 
characterized by a high concentration of both, green and roasted bean constituents, 
especially n-chlorogenic acid (252 mg/L) and NMP (76 mg/L). The caffeine level 
(720mg/L) was in the average range of conventional coffee brews. The ground 
coffee was delivered in vacuum bags (12.5 g each). Immediately before 
consumption, the coffee brew was freshly prepared using a Senseo coffee maker 
(Philips). Each individual consumed 250 mL of the coffee three times a day. 
 
Subjects 
The study was approved by the Griffith University Human Research Ethics 
Committee (EC00162). The final test population was comprised of 25 male and 26 
female (total n = 51), healthy non-smoking (age 18-61, BMI 19-38) Caucasians. 
Originally, 57 individuals were recruited, 6 individuals did not complete the trial for 
various reasons (gastric symptoms or sleeplessness after coffee consumption). All 
participants were regular coffee drinkers (2-6 cups of coffee/day). Participants were 
asked to maintain their usual dietary habits for the duration of the study, except for 
the coffee intake, caffeinated products, dietary supplements and foods rich in 
polyphenols. All volunteers were informed of the objectives of the study and consent 
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received for their participation. Exclusion criteria included smoking and the use of 
medication. In addition, competitive athletes were excluded. The 8-week intervention 
trial was designed as follows: weeks 1-2, 1st wash-out; weeks 3-6, coffee 
consumption and weeks 7-8, 2nd wash-out. During the consumption period, 
participants consumed 750mL of freshly brewed coffee (with/without sugar, addition 
of milk up to 50 mL) in three equal portions (morning, noontime, afternoon). During 
the two wash-out periods, the coffee brew was replaced by equal volumes of water. 
Nutritional reports covering a 7-day period were completed by participants in the last 
week of each study period. Urine/blood sampling was performed at the beginning of 
the study and on the last day of each study period in the morning, after a fasting 
period of at least 6 hours.  
 
Genomic DNA isolation 
For genomic DNA (gDNA) isolation, the QIAamp DNA Mini kit (QIAGEN) was used 
and gDNA purified as per the manufacturer’s instructions. The final concentration of 
DNA was quantified using a ND-1000 spectrophotometer (Nanodrop, Delaware). 
 
Sequencing 
SNPs rs35652124, rs6706649 and rs6721961: 
To obtain the 424bp amplicon of the polymorphic region of the NFE2L2 gene, 80ng 
of gDNA was amplified with 4µL of GoTaq® Flexi buffer (Promega), 2.5mM MgCl2, 
0.2mM dNTP, 0.2µM of each NFE2L2 primer (forward primer 5’–
GACCACTCTCCGACCTAAAGG–3’ and reverse primer 5’–
CGAGATAAAGAGTTGTTTGCGAA-3’) and 0.2µL GoTaq® to a total reaction volume 
of 20 µL. Amplification was performed on a VeritiTM 96-well Thermal Cycler (Applied 
Biosystems) with an initial step of 94°C x10 min, 30 cycles of 94°C x 45 sec, 55°C x 
45 sec and 72°C x 45s and a final extension of 72°C x 7 min. 5µL of PCR product 
was electrophoresed on 2% agarose gels stained with ethidium bromide for 30 min at 
80V. PCR products were purified with the ExoSAP-IT® PCR cleanup kit 
(Affymetrix/USB) according to the manufacturer’s instructions. DNA concentration 
was quantified using a ND-1000 spectrophotometer (Nanodrop, Delaware) and 
diluted to a concentration of 20ng/µL DNA. For the sequencing reaction 1µL of DNA 
was added to 5µL of BigDye Terminator v3 (BDT v3.1, Applied Biosystems), 1.3µL of 
each NFE2L2 primer and 3.0µL of 5X BDT v3.1 Sequencing buffer. Amplification 
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cycles were as follows: 96°C x 1 min, 30 cycles of 96°C x 10 sec, 50°C x 5 sec and 
60°C x 4 min followed by 4°C x 5 min, 10°C x 5 min and 4°C x 2min. The product 
was transferred to a 1.5ml tube and ethanol precipitated by adding 2 µL of iced cold 
3M sodium acetate (pH 5.2) and 2 µL of 125mM EDTA (pH 8.0). The sample was 
vortexed, centrifuged at 10,000 g for 5 min, followed by addition of 50 µL of 100% 
ethanol followed by repeated vortexing and re-spinning the samples at 10,000 g for 5 
min. Samples were then incubated for 15 min (RT), precipitated by centrifugation at 
10,000g followed by incubation at 4°C for 20 min. The pellet was then rinsed in 70% 
ethanol, vortexed and centrifuged at 10,000g at 4°C for 5 min. The pellet was dried 
using a DNA Speed Vac® (Savant) on high drying mode for 5 min. Samples were 
then resuspended in 15µL dH2O. The purified products were directly added into a 
Micro AmpTM optical 96 well reaction plate (Applied Biosystems) to be analyzed on a 
3130 genetic analyzer (Applied Biosystems).  
 
GST1A1 genotyping 
GST1A1 genotyping was carried out by RFLP analysis. For PCR amplification, gene-
specific primers (forward primer 5’-TGTTGATTGTTTGCCTGAAATT-3’; reverse 
primer 5’-GTTAACGCTGTCACCGTCCT-3’) were used to generate a 480bp PCR 
product spanning the polymorphism. For the amplification of GSTA1 40ng of gDNA 
was amplified with 4µL of GoTag® Flexi buffer (Promega), 2.5mM MgCl2, 0.2mM 
each dNTP, 0.1µM of each GST1A1 primer and 1U Taq polymerase added. 
Amplification was performed on a VeritiTM 96-well Thermal Cycler (Applied 
Biosystems) with an initial denaturation of 94°C x 10 min, 30 cycles of 94°C x 45 s, 
58°C x 45 s and 72°C x 45s, and a final extension of 72°C x 7 min. PCR products 
were electrophoresed on 2% agarose gels stained with ethidium bromide for 30 min 
at 80 V. A no template control was included to detect possible contamination issues. 
This PCR product was then digested with EAR1 (New England Biolabs, Beverly, 
Massachusetts, USA). PCR reaction products were digested using 4U of restriction 
enzyme Ear1, 2 µL of 10X Buffer and 18 µl PCR product for 5 h at 37◦C. A no 
template control was included. The digested products were resolved on a 4% 
ultrapure agarose gel post-stained with 20µL ethidium bromide for 10 min. The 
GST1A1*A genotype produced a band at 480bp. A heterozygote GST1A1*A/B 
resulted in three bands at 480, 380 and 100bp and the GST1A1*B genotype resulted 
in two bands at 380 and 100bp. 
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UGT1A1 genotyping by size fragment analysis 
First, PCR was performed using one unlabelled and one 5'-end 6-FAM labelled 
primer (forward primer: 5’-156-FAM/AAGTGAACTCCCTGCTACCTT-3’, reverse 
primer 5’-CCACTGGGATCAACAGTATCT-3’) resulting in a 253bp PCR product, 
flanking the polymorphic TA locus in the promoter region. Briefly, 80ng of gDNA was 
amplified with 4µL of GoTag® Flexi buffer (Promega), 2.5mM MgCl2, 0.2mM each 
dNTP, 0.1µM of each UGT1A1 primer. 1U Taq polymerase was added for a total 
reaction volume of 20µL. Amplification was performed on a VeritiTM 96-well Thermal 
Cycler (Applied Biosystems) with an initial denaturation of 94°C x 15 min, followed by 
30 cycles of 95°C x 30s, 58°C x 40s and 72°C x 40s, followed by a final extension of 
72°C for 7 min. Following amplification, PCR products were electrophoresed on 2% 
agarose gels stained with ethidium bromide for 30 min at 80V. A no template control 
was included to detect any contamination. For sequencing, 0.5µL of PCR product 
was administered to 0.25µL 1:10 diluted GeneScan™ 500 LIZ Size Standard 
(Applied Biosystems) and 9.25µL of HiDi formamide (Applied Biosystems). Samples 
were diluted 1:5, subjected to sequencing on the 3130 genetic analyzer (Applied 
Biosystems) for (TA)n, and scored via Gene Mapper v4.0 software (Applied 
Biosystems). Control DNAs from previously sequenced individuals known to have a 
6/6, 6/7 or 7/7 genotype were included in the PCR analysis. The amplified product 
yielded a 93-or a 95-base pair fragment, which corresponded to (TA)6 and (TA)7, 
respectively. 
 
Gene transcription by Q-PCR 
At each of the four different BC points, venous blood samples were collected in 
EDTA-tubes and stored at RT until the sampling period was completed. RNA was 
then extracted from the human PBLs, and Q-PCR performed as previously reported 
[15]. Total RNA was extracted from isolated PBLs following the manufactures 
handbook of the RNeasy®Mini Kit (QIAGEN, Hilden, Germany). Following this, 2µg 
RNA was reverse-transcribed using Oligo-dT primers and the Omniscript® Reverse 
Transcription Kit (QIAGEN, Hilden, Germany). cDNA obtained from the RT reaction 
(amount corresponding to 2µg of total RNA) was subjected to Q-PCR using 
QuantiTect SYBR® Green PCR (QIAGEN, Hilden, Germany). The primer assays 
used were: Hs_NFE2L2_1_SG, QT00027384. ß-Actin: Hs_ACTB_1_SG, 
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QT00095431 GST1A1: Hs_GST1A1_1_SG, QT00060739. GSTT1: 
Hs_GSTT1_2_SG, QT010751638. UGT1A1: Hs_UGT1A1_1_SG, QT00020860 
(QIAGEN, Hilden, Germany). Primer concentrations and Q-PCR reaction parameters 
were according to manufacturer's guidelines in QuantiTect SYBR® Green PCR 
Handbook 11/2005 (QIAGEN, Hilden, Germany). Each sample was amplified in 
triplicate. A no RevT control was included for all assays.  
 
Statistical analysis 
The fold changes in expression of the target gene relative to the internal control gene 
(ß-actin) was analyzed using Bio-Opticon Software and the CT data was imported 
into Microsoft Excel 03. Data of all assays was analyzed by the 2−ΔΔCT method. Data 
presented are the mean ± SD of the individuals, grouped according to their 
respective genotypes and presented as relative transcription of wash-out (BC1 or 
BC2) = 1. Significances indicated are calculated by Student’s t test (#p < 0.05 and ***, 
###p < 0.001). 
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